Narcolepsy: Pathophysiology and Genetic Predisposition

Principles and Practice of Sleep Medicine: Fifth Edition

Volumn , Issue , 2010, Pages 938-956

  Mignot, Emmanuel ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84906842664     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-6645-3.00084-0     Document Type: Chapter

References (182)

1. American Academy of Sleep Medicine International classification of sleep disorders. Diagnostic and coding manual 2005, American Academy of Sleep Medicine, Chicago. 2nd ed.
2. Guilleminault C, Mignot E, Partinen M Controversies in the diagnosis of narcolepsy. Sleep 1994, 17(Suppl. 8):S1-S6.
3. Aldrich MS The clinical spectrum of narcolepsy and idiopathic hypersomnia. Neurology 1996, 46:393-401.
4. Anic-Labat S, Guilleminault C, Kraemer HC, et al. Validation of a cataplexy questionnaire in 983 sleep-disorders patients. Sleep 1999, 22:77-87.
5. Overeem S, Mignot E, van Dijk JG, et al. Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol 2001, 18:78-105.
6. Dauvilliers Y, Billiard M, Montplaisir J Clinical aspects and pathophysiology of narcolepsy. Clin Neurophysiol 2003, 114:2000-2017.
7. Nishino S, Ripley B, Overeem S, et al. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000, 355:39-40.
8. Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000, 6:991-997.
9. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000, 27:469-474.
10. Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002, 59:1553-1562.
11. Kanbayashi T, Inoue Y, Chiba S, et al. CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia. J Sleep Res 2002, 11:91-93.
12. Krahn LE, Pankratz VS, Oliver L, et al. Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: relationship to cataplexy and HLA DQB1*0602 status. Sleep 2002, 25:733-736.
13. Mignot E, Hayduk R, Black J, et al. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 1997, 20:1012-1020.
14. Mignot E, Lin L, Rogers W, et al. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet 2001, 68:686-699.
15. Nishino S, Mignot E Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 1997, 52:27-78.
16. Guilleminault C Narcolepsy syndrome. Principles and practice of sleep medicine 2003, Saunders, Philadelphia. M.H. Kryger, T. Roth, W.C. Dement (Eds.).
17. Knecht CD, Oliver JE, Redding R, et al. Narcolepsy in a dog and a cat. J Am Vet Med Assoc 1973, 162:1052-1053.
18. Mitler MM, Boysen BG, Campbell L, et al. Narcolepsy-cataplexy in a female dog. Exp Neurol 1974, 45:332-340.
19. Baker TL, Foutz AS, McNerney V, et al. Canine model of narcolepsy: genetic and developmental determinants. Exp Neurol 1982, 75:729-742.
20. Hungs M, Fan J, Lin L, et al. Identification and functional analysis of mutations in the hypocretin (orexin) genes of narcoleptic canines. Genome Res 2001, 11:531-539.
21. Mignot E, Nishino S, Sharp LH, et al. Heterozygosity at the canarc-1 locus can confer susceptibility for narcolepsy: induction of cataplexy in heterozygous asymptomatic dogs after administration of a combination of drugs acting on monoaminergic and cholinergic systems. J Neurosci 1993, 13:1057-1064.
22. Shelton J, Nishino S, Vaught J, et al. Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs. Sleep 1995, 18:817-826.
23. Kushida CA, Baker TL, Dement WC Electroencephalographic correlates of cataplectic attacks in narcoleptic canines. Electroencephalogr Clin Neurophysiol 1985, 61:61-70.
24. Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999, 98:365-376.
25. Ripley B, Fujiki N, Okura M, et al. Hypocretin levels in sporadic and familial cases of canine narcolepsy. Neurobiol Dis 2001, 8:525-534.
26. Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999, 98:437-451.
27. Hara J, Beuckmann CT, Nambu T, et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 2001, 30:345-354.
28. Zhang S, Lin L, Kaur S, et al. The development of hypocretin (orexin) deficiency in hypocretin/ataxin-3 transgenic rats. Neuroscience 2007, 148:34-43.
29. Willie JT, Chemelli RM, Sinton CM, et al. Distinct narcolepsy syndromes in orexin receptor-2 and orexin null mice: molecular genetic dissection of non-REM and REM sleep regulatory processes. Neuron 2003, 38:715-730.
30. Kisanuki YY, Chemelli RM, Sinton CM, et al. The role of orexin receptor type-1 (OXIR) in the regulation of sleep. Sleep 2000, 23(Suppl. 2):A91.
31. Adamantidis AR, Zhang F, Aravanis AM, et al. Neural substrates of awakening probed with optogenetic control of hypocretin neurons. Nature 2007, 450:420-424.
32. Zeitzer JM, Mignot E Role of hypocretin/orexin in the neurobiology of sleep and alterness. Narcolepsy and hypersomnia 2007, 697. Informa Health Care USA, New York. C. Bassetti, M. Billiard, E. Mignot (Eds.).
33. Yamanaka A, Beuckmann CT, Willie JT, et al. Hypothalamic orexin neurons regulate arousal according to energy balance in mice. Neuron 2003, 38:701-713.
34. Chabas D, Foulon C, Gonzalez J, et al. Eating disorder and metabolism in narcoleptic patients. Sleep 2007, 30:1267-1273.
35. Fortuyn HA, Swinkels S, Buitelaar J, et al. High prevalence of eating disorders in narcolepsy with cataplexy: a case-control study. Sleep 2008, 31:335-341.
36. Dahmen N, Becht J, Engel A, et al. Prevalence of eating disorders and eating attacks in narcolepsy. Neuropsychiatr Dis Treat 2008, 4:257-261.
37. Zhang S, Zeitzer JM, Sakurai T, et al. Sleep/wake fragmentation disrupts metabolism in a mouse model of narcolepsy. J Physiol 2007, 581(Pt. 2):649-663.
38. Yokogawa T, Marin W, Faraco J, et al. Characterization of sleep in zebrafish and insomnia in hypocretin receptor mutants. PLoS Biol 2007, 5:e277.
39. Prober DA, Rihel J, Onah AA, et al. Hypocretin/orexin overexpression induces an insomnia-like phenotype in zebrafish. J Neurosci 2006, 26:13400-13410.
40. Mignot E Why we sleep: the temporal organization of recovery. PLoS Biol 2008, 6:e106.
41. Mignot E, Renaud A, Nishino S, et al. Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers. Psychopharmacology (Berl) 1993, 113:76-82.
42. Nishino S, Arrigoni J, Shelton J, et al. Desmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compounds. Sleep 1993, 16:706-712.
43. Siegel JM Brainstem mechanisms generating REM sleep. Principles and practice of sleep medicine 2003, Saunders, Philadelphia. M.H. Kryger, T. Roth, W.C. Dement (Eds.).
44. Wu MF, Gulyani SA, Yau E, et al. Locus coeruleus neurons: cessation of activity during cataplexy. Neuroscience 1999, 91:1389-1399.
45. Wu MF, John J, Boehmer LN, et al. Activity of dorsal raphe cells across the sleep-waking cycle and during cataplexy in narcoleptic dogs. J Physiol 2004, 554(Pt. 1):202-215.
46. Nishino S, Mao J, Sampathkumaran R, et al. Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res Online 1998, 1:49-61.
47. Wisor JP, Nishino S, Sora I, et al. Dopaminergic role in stimulant-induced wakefulness. J Neurosci 2001, 21:1787-1794.
48. Mignot E, Nishino S, Guilleminault C, et al. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 1994, 17:436-437.
49. Kanbayashi T, Honda K, Kodama T, et al. Implication of dopaminergic mechanisms in the wake-promoting effects of amphetamine: a study of d- and l-derivatives in canine narcolepsy. Neuroscience 2000, 99:651-659.
50. Honda Y Census of narcolepsy, cataplexy and sleep life among teenagers in Fujisawa City. Sleep Res Online 1979, 8:191.
51. Miller JD, Farber J, Gatz P, et al. Activity of mesencephalic dopamine and non-dopamine neurons across stages of sleep and walking in the rat. Brain Res 1983, 273:133-141.
52. Steinfels GF, Heym J, Strecker RE, et al. Behavioral correlates of dopaminergic unit activity in freely moving cats. Brain Res 1983, 258:217-228.
53. Willie JT, Renthal W, Chemelli RM, et al. Modafinil more effectively induces wakefulness in orexin-null mice than in wild-type littermates. Neuroscience 2005, 130:983-995.
54. Castelli MP, Ferraro L, Mocci I, et al. Selective gamma-hydroxybutyric acid receptor ligands increase extracellular glutamate in the hippocampus, but fail to activate G protein and to produce the sedative/hypnotic effect of gamma-hydroxybutyric acid. J Neurochem 2003, 87:722-732.
55. -/- mice. Br J Pharmacol 2003, 140:315-322.
56. Baker TL, Dement WC Canine narcolepsy-cataplexy syndrome: evidence for an inherited monoaminergic-cholinergic imbalance. Brain mechanisms of sleep 1985, 199-233. Raven Press, New York. D.J. McGinty, R. Drucker-Colin, A. Morrison, P.L. Parmeggiani (Eds.).
57. Aldrich MS The neurobiology of narcolepsy-cataplexy. Prog Neurobiol 1993, 41:533-541.
58. Miller JD, Faull KF, Bowersox SS, et al. CNS monoamines and their metabolites in canine narcolepsy: a replication study. Brain Res 1990, 509:169-171.
59. Kilduff TS, Bowersox SS, Kaitin KI, et al. Muscarinic cholinergic receptors and the canine model of narcolepsy. Sleep 1986, 9(1 Pt. 2):102-106.
60. Kish SJ, Mamelak M, Slimovitch C, et al. Brain neurotransmitter changes in human narcolepsy. Neurology 1992, 42:229-234.
61. Aldrich MS, Hollingsworth Z, Penney JB Dopamine-receptor autoradiography of human narcoleptic brain. Neurology 1992, 42:410-415.
62. Aldrich MS, Prokopowicz G, Ockert K, et al. Neurochemical studies of human narcolepsy: alpha-adrenergic receptor autoradiography of human narcoleptic brain and brainstem. Sleep 1994, 17:598-608.
63. Bowersox SS, Kilduff TS, Faull KF, et al. Brain dopamine receptor levels elevated in canine narcolepsy. Brain Res 1987, 402:44-48.
64. 11C-raclopride. Neurology 1994, 44:2102-2104.
65. 2 receptors. Neurology 1995, 45:1735-1738.
66. 2 receptors quantified in vivo in human narcolepsy. Biol Psychiatry 1997, 41:305-310.
67. Faull KF, Guilleminault C, Berger PA, et al. Cerebrospinal fluid monoamine metabolites in narcolepsy and hypersomnia. Ann Neurol 1983, 13:258-263.
68. Nishino S, Fujiki N, Ripley B, et al. Decreased brain histamine content in hypocretin/orexin receptor-2 mutated narcoleptic dogs. Neurosci Lett 2001, 313:125-128.
69. Nishino S, Shelton J, Reid MS, et al. Muscle atonia is triggered by cholinergic stimulation of the basal forebrain: implication for the pathophysiology of canine narcolepsy. J Neurosci 1995, 15(7 Pt. 1):4806-4814.
70. Reid MS, Nishino S, Tafti M, et al. Neuropharmacological characterization of basal forebrain cholinergic stimulated cataplexy in narcoleptic canines. Exp Neurol 1998, 151:89-104.
71. Reid MS, Tafti M, Nishino S, et al. Local administration of dopaminergic drugs into the ventral tegmental area modulates cataplexy in the narcoleptic canine. Brain Res 1996, 733:83-100.
72. -/- mice and patients. Neurobiol Dis 2008, 30:74-83.
73. de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 1998, 95:322-327.
74. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998, 92:573-585.
75. Hungs M, Mignot E Hypocretin/orexin, sleep and narcolepsy. Bioessays 2001, 23:397-408.
76. Taheri S, Zeitzer JM, Mignot E The role of hypocretins (orexins) in sleep regulation and narcolepsy. Annu Rev Neurosci 2002, 25:283-313.
77. Beuckmann CT, Yanagisawa M Orexins: from neuropeptides to energy homeostasis and sleep/wake regulation. J Mol Med 2002, 80:329-342.
78. Hungs M, Lin L, Okun M, et al. Polymorphisms in the vicinity of the hypocretin/orexin are not associated with human narcolepsy. Neurology 2001, 57:1893-1895.
79. Olafsdottir BR, Rye DB, Scammell TE, et al. Polymorphisms in hypocretin/orexin pathway genes and narcolepsy. Neurology 2001, 57:1896-1899.
80. Ripley B, Overeem S, Fujiki N, et al. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology 2001, 57:2253-2258.
81. Okun ML, Lin L, Pelin Z, et al. Clinical aspects of narcolepsy-cataplexy across ethnic groups. Sleep 2002, 25:27-35.
82. Fujiki N, Yoshida Y, Ripley B, et al. Changes in CSF hypocretin-1 (orexin A) levels in rats across 24 hours and in response to food deprivation. Neuroreport 2001, 12:993-997.
83. Yoshida Y, Fujiki N, Nakajima T, et al. Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. Eur J Neurosci 2001, 14:1075-1081.
84. Zeitzer JM, Buckmaster CL, Parker KJ, et al. Circadian and homeostatic regulation of hypocretin in a primate model: implications for the consolidation of wakefulness. J Neurosci 2003, 23:3555-3560.
85. Salomon RM, Ripley B, Kennedy JS, et al. Diurnal variation of cerebrospinal fluid hypocretin-1 (orexin-A) levels in control and depressed subjects. Biol Psychiatry 2003, 54:96-104.
86. Grady SP, Nishino S, Czeisler CA, et al. Diurnal variation in CSF orexin-A in healthy male subjects. Sleep 2006, 29:295-297.
87. Mignot E, Chen W, Black J On the value of measuring CSF hypocretin-1 in diagnosing narcolepsy. Sleep 2003, 26:646-649.
88. Marcus JN, Aschkenasi CJ, Lee CE, et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol 2001, 435:6-25.
89. Mignot E, Taheri S, Nishino S Sleeping with the hypothalamus: emerging therapeutic targets for sleep disorders. Nat Neurosci 2002, 5(Suppl.):1071-1075.
90. Lin JS, Hou Y, Sakai K, et al. Histaminergic descending inputs to the mesopontine tegmentum and their role in the control of cortical activation and wakefulness in the cat. J Neurosci 1996, 16:1523-1537.
91. Westphal C Eigenthumliche mit Einschlafen verbundene Anfalle. Arch Psychiat 1877, 7:631-635.
92. Krabbe E, Magnussen G On narcolepsy. I. Familial narcolepsy. Acta Psychiatr Scand 1942, 17:149.
93. Mignot E Genetic and familial aspects of narcolepsy. Neurology 1998, 50(2 Suppl. 1):S16-S22.
94. Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993, 328:1230-1235.
95. D'Alessandro R, Rinaldi R, Cristina E, et al. Prevalence of excessive daytime sleepiness an open epidemiological problem. Sleep 1995, 18:389-391.
96. Hublin C, Kaprio J, Partinen M, et al. Daytime sleepiness in an adult, Finnish population. J Intern Med 1996, 239:417-472.
97. Honda M, Honda Y, Uchida S, et al. Monozygotic twins incompletely concordant for narcolepsy. Biol Psychiatry 2001, 49:943-947.
98. Honda Y A monozygotic pair completely discorcordant for narcolepsy, with sleep deprivation as a possible precipitating factor. Sleep Biol Rhythms 2003, 1:147-149.
99. Dauvilliers Y, Maret S, Bassetti C, et al. A monozygotic twin pair discordant for narcolepsy and CSF hypocretin-1. Neurology 2004, 62:2137-2139.
100. Gill AW Idopathic and traumatic narcolepsy. Lancet 1941, 12:474.
101. Guilleminault C, Faull KF, Miles L, et al. Posttraumatic excessive daytime sleepiness: a review of 20 patients. Neurology 1983, 33:1584-1589.
102. Lankford DA, Wellman JJ, O'Hara C Posttraumatic narcolepsy in mild to moderate closed head injury. Sleep 1994, 17(Suppl. 8):S25-S28.
103. Orellana C, Villemin E, Tafti M, et al. Life events in the year preceding the onset of narcolepsy. Sleep 1994, 17(Suppl. 8):S50-S53.
104. Roth B Narcolepsy and hypersomnia 1980, Karger, Basel.
105. Mueller-Eckhardt G, Meier-Ewart K, Schiefer HG Is there an infectious origin of narcolepsy?. Lancet 1990, 335:424.
106. Dauvilliers Y, Carlander B, Molinari N, et al. Month of birth as a risk factor for narcolepsy. Sleep 2003, 26:663-665.
107. Dahmen N, Tonn P Season of birth effect in narcolepsy. Neurology 2003, 61:1016.
108. Honda Y, Asake A, Tanaka Y, et al. Discrimination of narcolepsy by using genetic markers and HLA. Sleep Res 1983, 12:254.
109. Juji T, Satake M, Honda Y, et al. HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive. Tissue Antigens 1984, 24:316-319.
110. Mueller-Eckhardt G, Meier-Ewert K, Schendel DJ, et al. HLA and narcolepsy in a German population. Tissue Antigens 1986, 28:163-169.
111. Langdon N, Welsh KI, van Dam M, et al. Genetic markers in narcolepsy. Lancet 1984, 2:1178-1180.
112. Roth B, Nevsimalova S, Sonka K, et al. A study of the occurrence of HLA DR2 in 124 narcoleptics: clinical aspects. Schweiz Arch Neurol Psychiatr 1988, 139:41-51.
113. Sachs C, Moller E The occurrence of HLA-DR2 in clinically established narcolepsy. Acta Neurol Scand 1987, 75:437-439.
114. Billiard M, Seignalet J, Besset A, et al. HLA-DR2 and narcolepsy. Sleep 1986, 9(1 Pt. 2):149-152.
115. Poirier G, Montplaisir J, Decary F, et al. HLA antigens in narcolepsy and idiopathic central nervous system hypersomnolence. Sleep 1986, 9(1 Pt. 2):153-158.
116. Mignot E, Tafti M, Dement WC, et al. Narcolepsy and immunity. Adv Neuroimmunol 1995, 5:23-37.
117. Carlander B, Eliaou JF, Billiard M Autoimmune hypothesis in narcolepsy. Neurophysiol Clin 1993, 23:15-22.
118. Black JL, Krahn LE, Pankratz VS, et al. Search for neuron-specific and nonneuron-specific antibodies in narcoleptic patients with and without HLA DQB1*0602. Sleep 2002, 25:719-723.
119. Overeem S, Geleijins K, Garssen MP, et al. Screening for anti-ganglioside antibodies in hypocretin-deficient human narcolepsy. Neurosci Lett 2003, 341:13-16.
120. Scammell TE The frustrating and mostly fruitless search for an autoimmune cause of narcolepsy. Sleep 2006, 29:601-602.
121. Thannickal TC, Siegel JM, Nienhuis R, et al. Pattern of hypocretin (orexin) soma and axon loss, and gliosis, in human narcolepsy. Brain Pathol 2003, 13:340-351.
122. Kaufmann C, Schuld A, Pollmacher T, et al. Reduced cortical gray matter in narcolepsy: preliminary findings with voxel-based morphometry. Neurology 2002, 58:1852-1855.
123. Draganski B, Geisler P, Hajak G, et al. Hypothalamic gray matter changes in narcoleptic patients. Nat Med 2002, 8:1186-1188.
124. Overeem S, Steens SC, Good CD, et al. Voxel-based morphometry in hypocretin-deficient narcolepsy. Sleep 2003, 26:44-46.
125. Mignot E, Lin X, Arrigoni J, et al. DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and black Americans. Sleep 1994, 17(Suppl. 8):S60-S67.
126. Mignot E, Kimura A, Lattermann A, et al. Extensive HLA class II studies in 58 non-DRB1*15 (DR2) narcoleptic patients with cataplexy. Tissue Antigens 1997, 49:329-341.
127. Ellis MC, Hetisimer AH, Ruddy DA, et al. HLA class II haplotype and sequence analysis support a role for DQ in narcolepsy. Immunogenetics 1997, 46:410-417.
128. Pelin Z, Guilleminault C, Risch N, et al. HLA-DQB1*0602 homozygosity increases relative risk for narcolepsy but not disease severity in two ethnic groups. US Modafinil in Narcolepsy Multicenter Study Group. Tissue Antigens 1998, 51:96-100.
129. Hong SC, Lin L, Lo B, et al. DQB1*0301 and DQB1*0601 modulate narcolepsy susceptibility in Koreans. Hum Immunol 2007, 68:59-68.
130. Mignot E, Lin X, Kalil J, et al. DQB1-0602 (DQw1) is not present in most nonDR2 Caucasian narcoleptics. Sleep 1992, 15:415-422.
131. Nakayama J, Miura M, Honda M, et al. Linkage of human narcolepsy with HLA association to chromosome 4p13-q21. Genomics 2000, 65:84-86.
132. Hohjoh H, Terada N, Nakayama T, et al. Case-control study with narcoleptic patients and healthy controls who, like the patients, possess both HLA-DRB1*1501 and -DQB1*0602. Tissue Antigens 2001, 57:230-235.
133. Kato T, Honda M, Kuwata S, et al. Novel polymorphism in the promoter region of the tumor necrosis factor alpha gene: no association with narcolepsy. Am J Med Genet 1999, 88:301-304.
134. Wieczorek S, Gencik M, Rujescu D, et al. TNFA promoter polymorphisms and narcolepsy. Tissue Antigens 2003, 61:437-442.
135. Dauvilliers Y, Neidhart E, Billiard M, et al. Sexual dimorphism of the catechol-O-methyltransferase gene in narcolepsy is associated with response to modafinil. Pharmacogenomics J 2002, 2:65-68.
136. Dauvilliers Y, Neidhart E, Lecendreux M, et al. MAO-A and COMT polymorphisms and gene effects in narcolepsy. Mol Psychiatry 2001, 6:367-472.
137. Kawashima M, Tamiya G, Oka A, et al. Genomewide association analysis of human narcolepsy and a new resistance gene. Am J Hum Genet 2006, 79:252-263.
138. Miyagawa T, Honda M, Kawashima M, et al. Polymorphism located between CPT1B and CHKB, and HLA-DRB1*1501-DQB1*0602 haplotype confer susceptibility to CNS hypersomnias (essential hypersomnia). PLoS ONE 2009, 4:e5394.
139. Miyagawa T, Kawashima M, Nishida N, et al. Variant between CPT1B and CHKB associated with susceptibility to narcolepsy. Nat Genet 2008, 40:1324-1328.
140. Hallmayer J, Faraco J, Lin L, et al. Narcolepsy is strongly associated with the TCR alpha locus. Nature Gen 2009.
141. Shiina T, Hosomichi K, Inoko H, et al. The HLA genomic loci map: expression, interaction, diversity and disease. J Hum Genet 2009, 54:15-39.
142. Evans RW Complications of lumbar puncture. Neurol Clin 1998, 16:83-105.
143. Bourgin P, Zeitzer JM, Mignot E CSF hypocretin-1 assessment in sleep and neurological disorders. Lancet Neurol 2008, 7:649-662.
144. Dalal MA, Schuld A, Pollmacher T Undetectable CSF level of orexin A (hypocretin-1) in a HLA-DR2 negative patient with narcolepsy-cataplexy. J Sleep Res 2002, 11:273.
145. Hecht M, Lin L, Kushida CA, et al. Immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin deficiency/narcolepsy. Sleep 2003, 26:809-810.
146. Kubota H, Kanbayashi T, Tanabe Y, et al. Decreased cerebrospinal fluid hypocretin-1 levels near the onset of narcolepsy in 2 prepubertal children. Sleep 2003, 26:555-557.
147. von Economo C Encephalitis lethargica ITS sequelae and treatment 1931, Oxford University Press, London.
148. von Economo C Sleep as a problem of localization. J Nerv Ment Dis 1930, 71:249-259.
149. Daniels LE Narcolepsy. Medicine 1934, 13:1-122.
150. Mignot E A hundred years of narcolepsy research. Arch Ital Biol 2001, 139:207-220.
151. Symonds CP Narcolepsy as a symptom of encephalitis lethargica. Lancet 1926, 12:1214-1215.
152. Adie WJ Idiopathic narcolepsy: a disease sui generis; with remarks on the mechanism of sleep. Brain 1926, 49:257-306.
153. Aldrich MS, Naylor MW Narcolepsy associated with lesions of the diencephalon. Neurology 1989, 39:1505-1508.
154. Nishino S, Kanbayashi T Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. Sleep Med Rev 2005, 9:269-310.
155. Fronczek R, Baumann CR, Lammers GJ, et al. Hypocretin/orexin disturbances in neurological disorders. Sleep Med Rev 2009, 13:9-22.
156. Arii J, Kanbayashi T, Tanabe Y, et al. A hypersomnolent girl with decreased CSF hypocretin level after removal of a hypothalamic tumor. Neurology 2001, 56:1775-1776.
157. Dempsey OJ, McGeoch P, De Silva RN, et al. Acquired narcolepsy in an acromegalic patient who underwent pituitary irradiation. Neurology 2003, 61:537-540.
158. Kato T, Kanbayashi T, Yamamoto K, et al. Hypersomnia and low CSF hypocretin-1 (orexin-A) concentration in a patient with multiple sclerosis showing bilateral hypothalamic lesions. Intern Med 2003, 42:743-745.
159. Kubota H, Kanbayashi T, Tanabe Y, et al. A case of acute disseminated encephalomyelitis presenting hypersomnia with decreased hypocretin level in cerebrospinal fluid. J Child Neurol 2002, 17:537-539.
160. Scammell TE, Nishino S, Mignot E, et al. Narcolepsy and low CSF orexin (hypocretin) concentration after a diencephalic stroke. Neurology 2001, 56:1751-1753.
161. Nozaki H, Shimohata T, Kanbayashi T, et al. A patient with anti-aquaporin 4 antibody who presented with recurrent hypersomnia, reduced orexin (hypocretin) level, and symmetrical hypothalamic lesions. Sleep Med 2009, 10:253-255.
162. Nelson GB, Hahn JS Stimulus-induced drop episodes in Coffin-Lowry syndrome. Pediatrics 2003, 111:197-202.
163. Parkes JD Genetic factors in human sleep disorders with special reference to Norrie disease, Prader-Willi syndrome and Moebius syndrome. J Sleep Res 1999, 8(Suppl. 1):14-22.
164. Kanbayashi T, Abe M, Fujimoto S, et al. Hypocretin deficiency in Niemann-Pick type C with cataplexy. Neuropediatrics 2003, 34:52-53.
165. Vankova J, Stepanova I, Jech R, et al. Sleep disturbances and hypocretin deficiency in Niemann-Pick disease type C. Sleep 2003, 26:427-430.
166. Oyama K, Takahashi T, Shoji Y, et al. Niemann-Pick disease type C: cataplexy and hypocretin in cerebrospinal fluid. Tohoku J Exp Med 2006, 209:263-267.
167. Smit LS, Lammers GJ, Catsman-Berrevoets CE Cataplexy leading to the diagnosis of Niemann-Pick disease type C. Pediatr Neurol 2006, 35:82-84.
168. Martinez-Rodriguez JE, Lin L, Iranzo A, et al. Decreased hypocretin-1 (Orexin-A) levels in the cerebrospinal fluid of patients with myotonic dystrophy and excessive daytime sleepiness. Sleep 2003, 26:287-290.
169. Melberg A, Ripley B, Lin L, et al. Hypocretin deficiency in familial symptomatic narcolepsy. Ann Neurol 2001, 49:136-137.
170. Katz ES, McGrath S, Marcus CL Late-onset central hypoventilation with hypothalamic dysfunction: a distinct clinical syndrome. Pediatr Pulmonol 2000, 29:62-68.
171. John J, Wu MF, Siegel JM Systemic administration of hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogs. Sleep Res Online 2000, 3:23-28.
172. Nishino S, Fujiki N, Yoshida Y, et al. The effects of hypocretin-1 in hypocretin receptor-2 mutated and hypocretin deficient narcoleptic dogs. Sleep 2003, 26(Suppl.):A287.
173. Deadwyler SA, Porrino L, Siegel JM, et al. Systemic and nasal delivery of orexin-A (hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci 2007, 27:14239-14247.
174. Mieda M, Willie JT, Hara J, et al. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci U S A 2004, 101:4649-4654.
175. Yoshida Y, Fujiki N, Maki RA, et al. Differential kinetics of hypocretins in the cerebrospinal fluid after intracereroventricular administration in rats. Neurosci Lett 2003, 346:182-186.
176. Schatzberg SJ, Barrett J, Cutter K, et al. The effect of hypocretin replacement therapy in a 3-year-old Weimaraner with narcolepsy. J Vet Intern Med 2004, 18:586-588.
177. Jackson MW, Reed JH, Smith AJ, et al. An autoantibody in narcolepsy disrupts colonic migrating motor complexes. J Neurosci 2008, 28:13303-13309.
178. Fronczek R, Verschuuren J, Lammers GJ Response to intravenous immunoglobulins and placebo in a patient with narcolepsy with cataplexy. J Neurol 2007, 254:1607-1608.
179. Valko PO, Khatami R, Baumann CR, et al. No persistent effect of intravenous immunoglobulins in patients with narcolepsy with cataplexy. J Neurol 2008, 255:1900-1903.
180. Dauvilliers Y, Carlander B, Rivier F, et al. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol 2004, 56:905-908.
181. Plazzi G, Poli F, Franceschini C, et al. Intravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexy. J Neurol 2008, 255:1549-1554.
182. Valko PO, Khatami R, Baumann CR, Bassetti CL No persistent effect of intravenous immunoglobulins in patients with narcolepsy with cataplexy. J Neurol 2008 Dec, 255:1900-1903.